If you are aHEALTHCARE PROVIDERwho treats patients with DMD
Learn MoreIf you are aPATIENT or a CAREGIVERof a person with DMD
Discover VILTEPSOIf you areLOOKING FOR SUPPORT and RESOURCES
Get Information
833-NSSUPRT (833-677-8778)
Monday–Friday, 8 AM-8 PM ET
NS Pharma is fully committed to providing ongoing support to DMD patients, their caregivers, and healthcare professionals.
Learn About NS SupportVILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
For more information about VILTEPSO, see full Prescribing Information.
For more information about VILTEPSO, see full Prescribing Information.